Non-Steroidal or Opioid Analgesia Use for Children With Musculoskeletal Injuries

NCT ID: NCT03767933

Last Updated: 2024-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

710 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-20

Study Completion Date

2023-03-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Musculoskeletal (MSK) injuries, including limb injuries, are the most common cause for Emergency Department (ED) visits for children with pain. Broken arms and legs are known to cause moderate to severe pain in most children, yet previous research shows that children's pain in the emergency department is still under-treated. Further, children are less likely to receive appropriate pain medicine than adults with similar injuries.

The purpose of this research study is to compare the effectiveness and safety of 3 different possible medication combinations, for the pain management of children with acute MSK limb injuries. The pain medicines the investigators are studying are ibuprofen (Advil/Motrin), acetaminophen (Tylenol/Tempra), and hydromorphone (Dilaudid).

This study will consist of 2 trials that will be run simultaneously. Eligible caregiver/ child pairs presenting to the emergency department with acute MSK limb injury will decide in which trial they wish to participate: the Opioid trial or the Non-Opioid trial. If they select the Non-opioid trial, they will have an equal chance of receiving either (a) Ibuprofen OR (b) Ibuprofen and acetaminophen. If they select the Opioid trial, they will have an equal chance of receiving either (a) Ibuprofen OR (b) Ibuprofen and acetaminophen OR (c) Ibuprofen and hydromorphone. Regardless of which study they choose, their child will, at minimum, receive Ibuprofen (Advil/Motrin) for their pain. All study medicines will be given in oral liquid form.

This study will help the investigators figure out which pain medicine or combination of pain medicines works best for children with limb injuries. Promotion of adequate acute pain treatment of children presenting to the ED may help prevent the known short and long-term effects of inadequately treated pain in children, including unpleasant memories, stress and anxiety upon future visits to healthcare, and compromised functional outcomes such as missed school.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale:

Multiple national and international organizations, including the American Academy of Pediatrics (AAP), have voiced concern over the emergency departments' (EDs) ability and willingness to provide appropriate analgesia for children's pain. Musculoskeletal (MSK) injury is a very common cause for ED visits for children with pain, with a child's risk of sustaining a fracture ranging from 27-42% by the age of 16 years. MSK injury is known to generate moderate to severe pain in most children and the ED serves as the critical entry point for these injured children. Despite three decades of pain research in this area, recent evidence confirms that ED pain management in children is still suboptimal. A retrospective cohort study of children presenting to the ED with an isolated long-bone fracture showed almost 1/3 received inadequate medication and 59% received no pain medications during the critical first hour of assessment. Previous studies have demonstrated that only 35% of children presenting to a Canadian pediatric ED with fractures or severe sprains received any analgesic. Further, a medical record review of two Canadian EDs showed unacceptably long delays in provision of initial analgesia, with children waiting a mean of 118 minutes to the provision of first analgesia.

The AAP's consensus statement on the assessment and management of pain in children recommends acetaminophen, ibuprofen, and opioids as the top three medication choices for the treatment of acute pain in children. These are also the top three most commonly used treatments in the ED for children with MSK injury pain. It stands to reason that clinicians (and certainly patients and their families) would prefer medication that has the best efficacy and safety profile. Although not based on robust evidence, there has recently been a concerted movement to limit opioid use in children. This is due, in part, to recent controversial publications and the Centre for Disease Control (CDC)'s position statement regarding opioid use in adults. Clinicians are increasingly less likely to prescribe oral opioids to younger children, and caregivers are increasingly less willing to accept or administer them.

Clinicians are currently seeking effective (and for many, non-opioid) oral analgesic options for their pediatric patients. Researchers have yet to identify the optimal acute pain management strategy for children with a suspected fracture, as very few studies of analgesic combination therapy for this injury exist, and monotherapy has been shown to be inadequate 50% of the time. This team's previous work has demonstrated that a combination of oral morphine with ibuprofen was no more effective and was less safe than oral ibuprofen, alone, for suspected fracture pain. Similarly, oxycodone was no more effective and was less safe than ibuprofen for post-discharge fracture pain. There is some emerging work from non-ED settings to suggest that oral hydromorphone may be an effective alternative to these two opioid medications. The investigators wish to study if acetaminophen or hydromorphone, when added to ibuprofen, offers more clinical pain relief than ibuprofen alone. They also wish to study if the combination of hydromorphone and ibuprofen is more clinically effective than the combination of acetaminophen with ibuprofen. This study, which will consist of two clinical trials, will inform health-care decisions by providing evidence for the effectiveness and safety of commonly prescribed analgesic combination therapies, and compare them to the most commonly used monotherapy, ibuprofen.

Methods:

This study will be comprised of two Phase 2, six-centre, randomized, double blind, placebo-controlled trials that will be run simultaneously. These two 'sister trials will be run simultaneously within this novel preference-informed complementary trial design. Caregiver/child pairs presenting to the ED with acute MSK limb injury will decide in which trial they wish to participate: the Opioid trial or the Non-Opioid trial.

Those willing to consider an Opioid will be randomized to receive either single-dose: (a) oral ibuprofen (10mg/kg, max 600mg) plus 2 placebos (both oral hydromorphone and acetaminophen), OR (b) oral ibuprofen (10mg/kg, max 600mg) + oral acetaminophen (15 mg/kg, max 1000mg) plus hydromorphone placebo OR (c) oral ibuprofen (10mg/kg) + oral hydromorphone (0.05 mg/kg, max 5 mg) plus acetaminophen placebo. Those not willing to consider an opioid will be enrolled in the Non-Opioid trial and will be randomized to receive a single dose of (a) oral ibuprofen (10mg/kg, max 600mg) + oral acetaminophen (15 mg/kg, max 1000mg) OR (b) oral ibuprofen (10mg/kg, max 600mg) + oral acetaminophen placebo. Those without a preference for either trial will be assigned to the Opioid trial, as this one includes all three options of possible medication combinations. The investigators will measure pain scores, assess safety, and acquire other study measures, at designated study time points.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Musculoskeletal Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study will be comprised of two Phase 2, six-centre, randomized, double blind, placebo-controlled trials that will be run simultaneously. The investigators expect that the number of participants recruited and the time to completion of both trials will be more efficient as recruitment for both will occur simultaneously. They propose to conduct this study with a novel preference-informed complementary trial design, in which they will conduct two simultaneous 'sister' trials. Caregiver/child pairs presenting to the ED with acute MSK limb injury will decide in which trial they wish to participate: the Opioid trial or the Non-Opioid trial. The design of each trial will be informed by its sister, or complementary, trial. Once the caregiver/child pair has chosen their preferred trial, conduct within each trial will follow traditional randomized, double-blind placebo-controlled superiority trial methodology. Study endpoints will be identical for both trials within this study.
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Research staff, emergency department staff, and participants will be masked with respect to the allocated treatment. The data analyst will also be masked using codes that will not identify treatment groups until analysis is complete.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-Opioid Trial: Arm 1

Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo, both administered once during the study at the time of recruitment.

Group Type ACTIVE_COMPARATOR

Ibuprofen

Intervention Type DRUG

10mg/kg, maximum 600mg; Oral liquid

Acetaminophen placebo

Intervention Type DRUG

Oral liquid

Non-Opioid Trial: Arm 2

Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen (15mg/kg, maximum 1000mg), both administered once during the study at the time of recruitment.

Group Type EXPERIMENTAL

Ibuprofen

Intervention Type DRUG

10mg/kg, maximum 600mg; Oral liquid

Acetaminophen

Intervention Type DRUG

15mg/kg, maximum 1000mg; Oral liquid

Opioid Trial: Arm 1

Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo + Oral hydromorphone placebo, all administered once during the study at the time of recruitment.

Group Type ACTIVE_COMPARATOR

Ibuprofen

Intervention Type DRUG

10mg/kg, maximum 600mg; Oral liquid

Acetaminophen placebo

Intervention Type DRUG

Oral liquid

Hydromorphone placebo

Intervention Type DRUG

Oral liquid

Opioid Trial: Arm 2

Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen (15mg/kg, maximum 1000mg) + Oral hydromorphone placebo, all administered once during the study at the time of recruitment.

Group Type EXPERIMENTAL

Ibuprofen

Intervention Type DRUG

10mg/kg, maximum 600mg; Oral liquid

Acetaminophen

Intervention Type DRUG

15mg/kg, maximum 1000mg; Oral liquid

Hydromorphone placebo

Intervention Type DRUG

Oral liquid

Opioid Trial: Arm 3

Oral ibuprofen (10mg/kg, max 600mg) + Oral acetaminophen placebo + Oral hydromorphone (0.05mg/kg, maximum 5 mg), all administered once during the study at the time of recruitment.

Group Type EXPERIMENTAL

Ibuprofen

Intervention Type DRUG

10mg/kg, maximum 600mg; Oral liquid

Hydromorphone

Intervention Type DRUG

0.05mg/kg, maximum 5 mg; Oral liquid

Acetaminophen placebo

Intervention Type DRUG

Oral liquid

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ibuprofen

10mg/kg, maximum 600mg; Oral liquid

Intervention Type DRUG

Acetaminophen

15mg/kg, maximum 1000mg; Oral liquid

Intervention Type DRUG

Hydromorphone

0.05mg/kg, maximum 5 mg; Oral liquid

Intervention Type DRUG

Acetaminophen placebo

Oral liquid

Intervention Type DRUG

Hydromorphone placebo

Oral liquid

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Advil Motrin Tylenol Tempra Dilaudid pms-Hydromorphone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Child aged 6-17 years
2. Presenting to the emergency department with an acute limb injury (\<24 hours old) that is neither obviously deformed nor having neuro-vascular compromise (as assessed by the triage nurse)
3. Self-reported pain score \> 5 on the 0 to 10 verbal Numerical Rating Scale at triage

Exclusion Criteria

1. Deemed to require immediate intravenous (IV) or intranasal (IN) pain medications by the clinical team
2. Previously known hypersensitivity to study medications
3. Acetaminophen or NSAID use within 3 hours prior to recruitment
4. Opioid use within 1 hour prior to recruitment
5. Caregiver and/or child cognitive impairment precluding the ability to self-report pain or respond to study questions
6. Injury suspected to be due to non-accidental trauma/ child abuse (as assessed by the triage nurse or reported by the family)
7. Suspected multi-limb fracture
8. Chronic pain that necessitates daily analgesic use
9. Hepatic or renal disease/dysfunction
10. Bleeding disorder
11. Known pregnancy
12. Vomiting that precludes the ability to take oral medications (as determined by the family)
13. Caregiver and/or child inability to communicate fluently in English or French in the absence of a native language interpreter
14. Caregiver unavailable for follow-up
15. Previous enrolment in the NO OUCH study
Minimum Eligible Age

6 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Manitoba

OTHER

Sponsor Role collaborator

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

Sponsor Role collaborator

University of Calgary

OTHER

Sponsor Role collaborator

The Hospital for Sick Children

OTHER

Sponsor Role collaborator

University of Ottawa

OTHER

Sponsor Role collaborator

Western University

OTHER

Sponsor Role collaborator

University of Alberta

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Samina Ali, MD

Role: PRINCIPAL_INVESTIGATOR

University of Alberta/Stollery Children's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alberta Children's Hospital

Calgary, Alberta, Canada

Site Status

Stollery Children's Hospital Emergency Department

Edmonton, Alberta, Canada

Site Status

Children's Hospital of Winnipeg

Winnipeg, Manitoba, Canada

Site Status

Childrens Hospital at London Health Sciences

London, Ontario, Canada

Site Status

Children's Hospital of Eastern Ontario

Ottawa, Ontario, Canada

Site Status

CHU Sainte-Justine

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Ali S, Dworsky-Fried Z, Moir M, Bharadia M, Rajagopal M, Gouin S, Sawyer S, Pellerin S, Bourrier L, Poonai N, Stang A, Leung J, van Manen M; KidsCAN PERC Innovative Pediatric Clinical Trials No OUCH Study Team. Factors Influencing Parental Decision-Making Regarding Analgesia for Children with Musculoskeletal Injury-Related Pain: A Qualitative Study. J Pediatr. 2023 Jul;258:113405. doi: 10.1016/j.jpeds.2023.113405. Epub 2023 Apr 4.

Reference Type DERIVED
PMID: 37023945 (View on PubMed)

Heath A, Yaskina M, Hopkin G, Klassen TP, McCabe C, Offringa M, Pechlivanoglou P, Rios JD, Poonai N, Ali S; KidsCAN PERC Innovative Pediatric Clinical Trials No OUCH Study Group. Non-steroidal or opioid analgesia use for children with musculoskeletal injuries (the No OUCH study): statistical analysis plan. Trials. 2020 Sep 3;21(1):759. doi: 10.1186/s13063-020-04503-y.

Reference Type DERIVED
PMID: 32883371 (View on PubMed)

Ali S, Rajagopal M, Klassen T, Richer L, McCabe C, Willan A, Yaskina M, Heath A, Drendel AL, Offringa M, Gouin S, Stang A, Sawyer S, Bhatt M, Hickes S, Poonai N; KidsCAN PERC Innovative Pediatric Clinical Trials No OUCH Study Team. Study protocol for two complementary trials of non-steroidal or opioid analgesia use for children aged 6 to 17 years with musculoskeletal injuries (the No OUCH study). BMJ Open. 2020 Jun 21;10(6):e035177. doi: 10.1136/bmjopen-2019-035177.

Reference Type DERIVED
PMID: 32565458 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro00073476

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Supracondylar Post-Operative Pain Study
NCT03759028 RECRUITING PHASE4
Opioid Laws and Pediatric Use
NCT04543227 COMPLETED
Morphine or Ketamine for Analgesia
NCT06835504 NOT_YET_RECRUITING PHASE3
Morphine PK Subgroup Analysis
NCT01322191 COMPLETED PHASE4